J Transl Med April 2016 PMID 27118048

Changing R&D models in research-based pharmaceutical companies.

Alexander Schuhmacher, Oliver Gassmann, Markus Hinder

Full text PDF Download social card

Mentions

Peak: 6 in Apr 2021

across 4 sources since Apr 2021

Extended reach

154,063

potential audience

Total likes

999

Video views

7,386

Mentions per month

Apr 2021 – Jan 2024

Where it's discussed

News26 articles
X / Twitter9 posts
Blogs4 articles
YouTube2 videos

AI synopsis

What people are saying

The social discussions primarily serve to share the publication with minimal commentary, exemplified by posts using hashtags like #R&D and #Pharmaceutical companies, which signals awareness rather than deep engagement. The tone and brevity suggest a recognition of the topic’s importance but lack detailed analysis or calls to action.

AgreementModerate agreement

Both discussions acknowledge the importance of changing R&D models in pharma, indicating general agreement on the article's relevance.

InterestModerate interest

The discussions show some interest, especially with hashtags highlighting key topics, but lack in-depth analysis or enthusiasm.

EngagementNeutral engagement

The posts are brief and mostly share the publication, reflecting minimal detailed engagement or critical thinking.

ImpactNeutral impact

The discussions do not seem to influence further conversations significantly or suggest widespread change, leading to a neutral impact rating.

Abstract in brief

Research-based pharmaceutical companies rely on developing new drugs to meet medical needs, but their efficiency in research and development (RD) has decreased over time.
To improve RD efficiency, companies are adopting strategies such as reducing project risks, lowering RD costs through outsourcing and risk-sharing, and boosting innovation potential via open innovation methods like open source centers and crowdsourcing.
Depending on their strategic focus, companies can position themselves as open innovators, knowledge creators, knowledge integrators, or knowledge levers, to optimize their RD processes and outcomes.

Read the full abstract

All mentions

Exploring Parasitic Relationships in Nature and the Rise of Fascism

On this Wednesday's BlaBlaNews, Emilio Garcia discusses the relationship between praying mantises and their parasites, highlighting their impact on drug research, and examines the global rise of fascism. The video…

BlaBlaLogia · Jan 17, 2024 5,544 views

Improving Pharmaceutical R&D Efficiency Through Open Innovation Strategies

This video discusses how research-based pharmaceutical companies are adopting new R&D models to enhance efficiency. Strategies include reducing project risks, outsourcing, risk-sharing, and leveraging open innovation…

BlaBlaLogia · Jan 30, 2024 1,842 views

Zé Floresta - Muda Floresta

@jebpaiva · X

RT @milio_blabla: https://t.co/IureRpvDjE

Jan 17, 2024 · 1 share · 2,073 followers View post →

@LVampre84526 · X

https://t.co/7EYnESYkCM

Jan 17, 2024 · 20 followers View post →

Emilio Garcia

@milio_blabla · X

https://t.co/IureRpvDjE

Jan 17, 2024 · 5 likes · 1 share · 3,909 followers View post →

Ronita De, PhD

@dronita_de · X